High BCL-2 expression, regardless of microarray-based classification, has also recently been reported to define a subset of DLBCL patients with a clinically superior outcome in response to R-CHOP therapy [25]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.